Yearend – Alligator Bioscience

2024-02-082024-02-14

Regulatory

Alligator Bioscience AB reports full year financial results for 2023 and for Q4 2023 and provides a business update

Mitazalimab meets OPTIMIZE-1 Phase 2 primary endpoint, demonstrating 40.4% Overall Response Rate and median Overall Survival of 14.3 months ...

2023-02-10

Interim results from mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer exceed 50% Objective Response Rate, the trial passes pre-plan ...

2022-02-112022-05-17

Regulatory

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...

2021-02-26

Regulatory

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...

2020-02-12

Regulatory

"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...

2019-02-14

Regulatory

The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...

2018-02-16

Regulatory

The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...

2017-02-17

Regulatory

Summary During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this were new shares ...